{"id":60412,"date":"2024-02-28T06:47:45","date_gmt":"2024-02-28T06:47:45","guid":{"rendered":"https:\/\/medsname.com\/rasalect\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rasalect","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/rasalect\/","title":{"rendered":"Rasalect"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snabbt svar<\/h3>\n

Rasalect<\/strong> \u00e4r en oral rasagiline<\/strong> (1 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> anv\u00e4nds f\u00f6r att behandla Parkinsons sjukdom<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Unlike selegiline, rasagiline is inte<\/em> metabolised to amphetamine derivatives, so insomnia is much less of a problem. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. Viktigt:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotoninsyndrom<\/em>.<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n

What Is Rasalect?<\/h2>\n

Rasalect is an oral tablet containing rasagiline 1 mg<\/strong>. rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Azilect<\/strong>. Rasalect is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Rasagiline was developed as a second-generation MAO-B inhibitor specifically to avoid selegiline’s amphetamine metabolites. It has a clean active metabolite (aminoindan) which itself has neuroprotective properties in laboratory models. Rasagiline can be used as monotherapy in early Parkinson disease or as adjunct to levodopa for end-of-dose wearing-off.<\/p>\n

How Does Rasalect (rasagiline) Work?<\/h2>\n

Rasagiline irreversibly inactivates MAO-B in the brain, slowing the breakdown of dopamine. Like selegiline it is selective for MAO-B at therapeutic doses (1 mg\/day) but loses selectivity above 1.5–2 mg\/day. Its main metabolite, aminoindan, has its own potential neuroprotective activity in preclinical models — the basis for the ADAGIO disease-modification trial, which produced suggestive but not conclusive results.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
Funktion<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Typical dose<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\nNej<\/td>\nNej<\/td>\nJa<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
Indikation<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nL\u00e5g<\/td>\nL\u00e5g<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Rasalect For?<\/h2>\n

Rasalect is appropriate for adults with Parkinson disease — either as monotherapy in early disease or as adjunct to levodopa in patients with motor fluctuations. Compared with selegiline, rasagiline is preferred when insomnia is a concern. Compared with safinamide, rasagiline is the better monotherapy option (safinamide is licensed only as adjunct).<\/p>\n

Dosering och administration<\/h2>\n

Den vanliga dosen f\u00f6r vuxna \u00e4r 1 mg en g\u00e5ng dagligen<\/strong>, taken in the morning with or without food. There is no need for titration — full effect is reached within 1–2 weeks. Doses above 1 mg\/day are generally avoided as MAO-B selectivity is lost. In moderate hepatic impairment reduce to 0.5 mg\/day; in severe hepatic impairment avoid.<\/p>\n\n\n\n\n\n\n\n
Population<\/th>\nDos<\/th>\n<\/tr>\n<\/thead>\n
Standard adult<\/td>\n1 mg once daily, morning<\/td>\n<\/tr>\n
Mild leversvikt<\/td>\n0.5 mg once daily<\/td>\n<\/tr>\n
Moderate-severe hepatic impairment<\/td>\nUndvik<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally inte<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

Vanliga biverkningar<\/h2>\n

Headache (the most common — usually transient), arthralgia, dyspepsia, depression, postural hypotension, flu-like symptoms. Less common: hallucinations, insomnia (much less than selegiline), weight loss, falls. With levodopa: increased dyskinesia.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause serotoninsyndrom<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

L\u00e4kemedels- och matinteraktioner<\/h2>\n